Hospira
Investor RelationsNewsroomCareersIn the Community
United States
  • Products + Services
    • Drugs
    • IV Sets
    • IV Clinical Integration
    • Infusion Pumps
    • Clinical Software
    • Implementation Services
    • Clinical Services
    • Contract Manufacturing
  • Healthcare Trends
    • Supply Costs
    • Medication Errors
    • IV Clinical Integration
    • Healthcare Associated Infections
    • Caregiver Safety
  • Support Center
    • Support - Infusion Pumps + Software
    • Order + Sales Support
    • Medical Affairs + Information
    • Clinical Bulletins
    • Customer Communications
  • About Hospira
    • Our Philosophy
    • Our History
    • Leadership
    • Awards + Recognition
    • Supplier Information
    • Newsroom
    • Investor Relations
    • Government Affairs
    • In the Community
    • Careers
    • Investor Relations
    • Acquisition Press Releases
    Email Print

    Acquisition Press Releases

     

    All Releases | Reset Search
    Acquisitions | Business/Product | Corporate | Financial

    2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
    DateTitle 
    08/22/10Hospira Japan Receives Approval for New Indication for 'Precedex IV(TM) 200ug'Printer Friendly Version
    07/01/10Hospira Announces Successful Completion of Tender Offer for Shares of Javelin PharmaceuticalsPrinter Friendly Version
    06/28/10Hospira Announces Intention to Complete Tender Offer for Shares of Javelin PharmaceuticalsPrinter Friendly Version
    06/17/10Hospira Announces Further Extension of Tender Offer for Shares of Javelin PharmaceuticalsPrinter Friendly Version
    06/03/10Hospira Announces Further Extension of Tender Offer for Shares of Javelin PharmaceuticalsPrinter Friendly Version
    05/19/10Hospira Announces Extension of Tender Offer for Shares of Javelin PharmaceuticalsPrinter Friendly Version
    04/19/10Hospira and Javelin Pharmaceuticals Enter Into Definitive Merger Agreement for Hospira to Acquire Javelin Pharmaceuticals; Hospira Will Initiate Tender OfferPrinter Friendly Version
    02/10/10Hospira Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of Orchid's Generic Injectable Pharmaceuticals BusinessPrinter Friendly Version

    Investing Overview

    • Shareholder Information
    • Stock Quote / Chart
    • Shareholder FAQ
    • Analyst Coverage
    • Information Request

    Financial Reports

    • Annual Reports / Proxies
    • Quarterly Reports / Supplemental Tables
    • Proxy Materials
    • SEC Filings
    • Insider Transactions

    News & Events

    • Press Releases
    • Presentations
    • Event Calendar
    • Email Alerts

    Corporate Governance

    • Hospira Leadership
    • Board of Directors
    • Board Committees and Charters
    • Corporate Governance Guidelines
    • Share Ownership Guidelines
    • Long Term Incentives Policy
    • Hospira Code of Business Conduct

    Investor Toolkit

    IR Contacts
    Email Alerts
    RSS Feeds
    Products + Services
    • Drugs
    • IV Sets
    • IV Clinical Integration
    • Infusion Pumps
    • Clinical Software
    • Implementation Services
    • Clinical Services
    • Contract Manufacturing
    • Drugs A-Z
    • Export Product Catalog
    • Buy at e.Hospira.com
    • Solution Center
    • Lidocaine
    • Sodium Bicarbonate
    • Sodium Chloride
    • Ketorolac
    • Morphine
    Healthcare Trends
    • Supply Costs
    • Medication Errors
    • IV Clinical Integration
    • Healthcare Associated Infections
    • Caregiver Safety
    Support Center
    • Support - Infusion Pumps + Software
    • Order + Sales Support
    • Medical Affairs + Information
    • Clinical Bulletins
    • Customer Communications
    About Hospira
    • Our Philosophy
    • Our History
    • Leadership
    • Awards + Recognition
    • Supplier Information
    • Newsroom
    • Investor Relations
    • Government Affairs
    • In the Community
    • Careers
    Follow Hospira
    • Follow us on Twitter
    • Follow us on YouTube
    • Follow us on LinkedIn
    Utility
    • Legal Notice
    • Privacy Policy
    • Compliance
    • Terms + Conditions
    © Hospira, Inc. This website and its information is intended for use by United States residents only. Regulatory requirements, data requirements or medical practices may differ between countries. Therefore, information on this site may be inappropriate for use outside of the United States. Site contents are intended for informational purposes only and not intended to replace discussion with a healthcare provider. If you have any questions regarding this site, contact Hospira.